Can a benzodiazepine be combined safely with Vyvanse (lisdexamfetamine)?

Benzodiazepines and Vyvanse: Avoid Concurrent Use Whenever Possible

Benzodiazepines should generally be avoided when prescribing Vyvanse (lisdexamfetamine), as this combination increases risks of oversedation, respiratory depression, and potentially fatal outcomes, particularly when combined with other CNS depressants.

Primary Safety Concerns

The FDA label for Vyvanse does not explicitly contraindicate benzodiazepine co-administration, but multiple clinical guidelines warn against combining CNS stimulants with CNS depressants 1. The most significant concern is additive CNS depression leading to respiratory compromise.

Evidence from Clinical Guidelines

The 2018 ESMO delirium guidelines specifically caution that combining benzodiazepines with certain medications carries risk of oversedation and respiratory depression 2. While these guidelines address olanzapine-benzodiazepine combinations in cancer patients, the principle of avoiding concurrent CNS depressants applies broadly.

The 2016 CDC opioid prescribing guideline provides the most relevant framework: concurrent benzodiazepine use with other CNS-active medications increases overdose risk nearly four-fold 3. Although this specifically addresses opioids, the mechanism—additive respiratory depression—applies to any CNS depressant combination.

Pharmacodynamic Considerations

Research on procedural sedation demonstrates that benzodiazepines alone cause minimal respiratory depression, but when combined with other CNS depressants, hypoxemia occurs in 92% of subjects and apnea in 50% 4. This synergistic effect is the core safety concern.

Clinical Decision Algorithm

When a patient on Vyvanse requires anxiolytic treatment:

1. First-line approach: Use evidence-based psychotherapy (CBT) rather than pharmacotherapy 3

2. If medication is necessary: Consider non-benzodiazepine alternatives:

   • SSRIs or SNRIs for generalized anxiety
   • Buspirone for anxiety (non-sedating)
   • Hydroxyzine for acute anxiety (antihistamine, less respiratory risk)

3. If benzodiazepines are unavoidable (e.g., severe panic disorder, alcohol withdrawal):

   • Use the lowest effective dose
   • Prescribe short-acting agents (lorazepam, alprazolam) rather than long-acting
   • Schedule frequent monitoring (weekly initially)
   • Educate patient about signs of respiratory depression
   • Strongly consider prescribing naloxone despite it not reversing benzodiazepines—it addresses polysubstance risk
   • Check state PDMP to identify other CNS depressants 3

Special Populations

Adolescents and young adults on Vyvanse: The ADHD practice guideline notes that lisdexamfetamine has lower abuse potential than immediate-release stimulants 5. However, this population may be at higher risk for substance experimentation. Screen for substance use before prescribing either medication 5.

Patients with insomnia: The 2008 insomnia guideline recommends benzodiazepine receptor agonists for sleep 6, but in patients on Vyvanse, address stimulant-induced insomnia first:

• Ensure Vyvanse is taken early morning
• Assess for adequate dosing (too high causes insomnia)
• Consider switching to shorter-acting stimulant if evening symptoms problematic
• Use behavioral sleep interventions before adding sedatives

Tapering Considerations

If a patient is already on both medications, do not discontinue abruptly. The 2025 benzodiazepine tapering guideline emphasizes gradual reduction to prevent withdrawal seizures 7. The CDC guideline suggests tapering opioids before benzodiazepines when both are prescribed, as benzodiazepine withdrawal is more dangerous 3. This same principle applies to stimulants—continue Vyvanse while tapering benzodiazepines using a 25% dose reduction every 1-2 weeks 3.

Common Pitfalls

• Assuming low-dose benzodiazepines are safe: Even therapeutic doses increase respiratory depression risk when combined with other CNS-active drugs
• Overlooking alcohol use: Patients may not volunteer alcohol consumption, which dramatically increases risk when combined with benzodiazepines and stimulants
• Prescribing for stimulant-induced anxiety: This creates a problematic cycle—address the underlying stimulant dosing or timing issue instead
• Failing to check PDMP: Patients may receive benzodiazepines from multiple prescribers

Monitoring Requirements

If concurrent use is unavoidable:

• Baseline: Respiratory rate, oxygen saturation, mental status
• Weekly visits initially, then monthly once stable
• Urine drug testing to confirm adherence and detect undisclosed substances 3
• Assess for signs of CNS depression: excessive sedation, confusion, slowed breathing
• Document medical necessity and risk-benefit discussion in chart

The safest approach is to avoid this combination entirely through use of non-pharmacologic interventions and alternative medications that don't carry synergistic respiratory depression risk.